Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by barmac6on Nov 11, 2011 10:08am

228 Views

Post# 19229406

RE: Insider buy

a little buying and lots of options expiering....

Latest 10 SEDI filings (by filing date) for HEM within the last 6 months	[?]
Amended Filing

					As of 11:59pm ET November 10th, 2011
Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	# or value acquired or disposed of	Unit Price
Nov 10/11	Nov 10/11	Lang, Michael James	Direct Ownership	Common Shares	10 - Acquisition in the public market	18,500	.620
Nov 2/11	Nov 2/11	Whitehead, Michael Lloyd	Direct Ownership	Options	52 - Expiration of options	-50,000
Nov 2/11	Nov 2/11	Smith, Lisa Marie	Direct Ownership	Options	52 - Expiration of options	-8,333
Nov 2/11	Nov 2/11	Miller, Steven Ralph	Direct Ownership	Options	52 - Expiration of options	-20,000
Oct 11/11	Oct 11/11	Batcheller, Barry D.	Direct Ownership	Common Shares	10 - Acquisition in the public market	15,001	.637
Oct 11/11	May 25/06	Batcheller, Barry D.	Direct Ownership	Common Shares	00 - Opening Balance-Initial SEDI Report
Oct 4/11	Jan 7/08	Smith, Lisa Marie	Direct Ownership	Common Shares	10 - Disposition in the public market	-5,556	$3.68
Sep 28/11	Apr 9/05	Heiniger, Richard Wayne	Indirect Ownership	Common Shares	00 - Opening Balance-Initial SEDI Report
Sep 28/11	Aug 25/11	Heiniger, Richard Wayne	Indirect Ownership	Common Shares	10 - Disposition in the public market	-58,500	.820
Sep 28/11	Aug 30/11	Heiniger, Richard Wayne	Indirect Ownership	Common Shares	10 - Disposition in the public market	-10,000	.820